Results 191 to 200 of about 40,669 (305)

Sintilimab plus cisplatin and nab‐paclitaxel induction treatment for locally advanced borderline‐resectable oesophageal squamous cell carcinoma: A single‐arm, prospective, phase 2 study (NEOCRTEC2001)

open access: yesClinical and Translational Medicine, Volume 16, Issue 5, May 2026.
To the best of our knowledge, this is the first trial to evaluate the sintilimab combined with chemotherapy as an induction treatment for patients with BR‐ESCC. The R0 resection rate in this study was 56.0%, and the pCR rate was 18.0%. Patients who achieved R0 resection exhibited improved survival outcomes.
Jia‐Di Wu   +12 more
wiley   +1 more source

Critical care of the liver transplant patient [PDF]

open access: yes, 1988
Esquivel, CO   +4 more
core  

Liver Transplantation Outcomes in Crigler‐Najjar Syndrome in Iran: A Single‐Center Retrospective Cohort Study Over 20 Years

open access: yesHealth Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims Crigler‐Najjar Syndrome (CNS) is a rare autosomal recessive disorder caused by uridine diphosphate glucuronosyltransferase (UGT1A1) deficiency, leading to unconjugated hyperbilirubinemia. Without treatment, patients are at high risk of kernicterus and irreversible neurological damage.
Sajad Teimoury   +6 more
wiley   +1 more source

Five‐year outcomes of pembrolizumab versus chemotherapy in Chinese patients with non‐small‐cell lung cancer and programmed cell death ligand 1 tumor proportion score ≥1%: KEYNOTE‐042 China study

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2429-2439, 1 May 2026.
What's new? Global research has found that for people newly diagnosed with advanced non‐small cell lung cancer (NSCLC), the anti‐PD‐1 monoclonal antibody pembrolizumab on its own often leads to better results than traditional chemotherapy. The present report details long‐term findings of pembrolizumab therapy specifically among Chinese patients.
Yi‐Long Wu   +14 more
wiley   +1 more source

Efficacy and safety of fruquintinib combined with albumin‐bound paclitaxel as second‐line therapy for advanced gastric cancer following failure of PD‐1 inhibitor‐containing treatment (TACTIC GC‐01): A phase II single‐arm study

open access: yesInternational Journal of Cancer, Volume 158, Issue 9, Page 2219-2228, 1 May 2026.
What's new? Anti‐angiogenic drugs have shown promising efficacy as a second‐line treatment for advanced gastric cancer. However, it remains unclear how alterations in the tumor microenvironment following first‐line immunotherapy may impact tumor angiogenesis and influence subsequent therapeutic outcomes. This single‐arm study prospectively explored the
Xiaoting Ma   +11 more
wiley   +1 more source

Acquired Angioedema Associated With Systemic Lupus Erythematosus Presenting as Acute Abdomen: A Case Report

open access: yesJournal of General and Family Medicine, Volume 27, Issue 3, May 2026.
ABSTRACT Acquired angioedema (AAE) due to C1 inhibitor deficiency can present as acute abdomen. A 24‐year‐old woman developed severe abdominal pain and bowel wall edema initially suggestive of hereditary angioedema, but genetic testing excluded it. She later manifested fever, arthritis, rash, and serological abnormalities consistent with systemic lupus
Seiji Shiota   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy